| Website | clarusventures.com |
| Phone | 617.949.2200 |
| Employees | |
| Description | Venture capital firm |
Clarus Ventures is a life sciences venture capital firm founded by a team of accomplished investment professionals with extensive and complementary industry backgrounds which have enabled them to establish a long history of success in creating value. Their deep relationships with world thought leaders and decision makers allow this team to identify unique investment opportunities and shepherd them to maturity. Clarus augments its core expertise of investing in biopharmaceuticals and medical technology companies with the deep and diverse expertise of the team in research and development, commercialization, business development and operations management at the global level. Clarus has $1.2 billion of assets under management across two lifesciences dedicated funds
| Company | Date | Round | Size | Participants |
| Catabasis Pharmaceuticals | 2/13 | Venture Round | $9M | 4 |
| Avillion | 1/13 | Venture Round | 2 | |
| NanoString Technologies | 12/12 | Series E | $15.3M | 7 |
| Pearl Therapeutics | 11/12 | Series D | $65M | 4 |
| Oxford Immunotec | 6/12 | Venture Round | $28M | 8 |
| Catabasis Pharmaceuticals | 12/11 | Series A | $8M | 4 |
| NanoString Technologies | 11/11 | Series D | $20M | 5 |
| Cleave Biosciences | 10/11 | Series A | $44M | 5 |
| Restoration Robotics | 8/11 | Series C | $41M | 4 |
| SARcode Bioscience | 7/11 | Series B | $44M | 4 |
| Aerie Pharmaceuticals | 3/11 | Series B | $30M | 4 |
| TyRx Pharma | 12/10 | Venture Round | $20M | 3 |
| Achillion Pharmaceuticals | 8/10 | Venture Round | $50.1M | 4 |
| TetraLogic Pharmaceuticals | 8/10 | Series C | $32M | 8 |
| Zogenix | 7/10 | Venture Round | $15M | 5 |
| FerroKin Biosciences | 6/10 | Series B | $12M | 5 |
| Oxford Immunotec | 5/10 | Series D | $26M | 7 |
| Catabasis Pharmaceuticals | 4/10 | Series A | $39M | 4 |
| Pearl Therapeutics | 3/10 | Series C | $15M | 3 |
| NanoString Technologies | 2/10 | Venture Round | $15M | 1 |
| Neomend | 1/10 | Series D | $30M | 5 |
| Ophthotech | 12/09 | Series B | $30M | 4 |
| Virdante Pharmaceuticals | 11/09 | Series A | $30M | 6 |
| Zogenix | 10/09 | Series B | $36M | 5 |
| NanoString Technologies | 6/09 | Series C | $30M | 3 |
| Lycera | 5/09 | Series A | $36M | 4 |
| Aerovance | 4/09 | Venture Round | $38M | 8 |
| Biolex Therapeutics | 10/08 | Series D | $60M | 12 |
| ESBATech | 8/08 | Series B | $22M | 7 |
| Pearl Therapeutics | 7/08 | Series A | $18M | 4 |
| Zogenix | 1/08 | Venture Round | $18M | 4 |
| Taligen Therapeutics | 1/08 | Series B | $65M | 4 |
| Pelikan Technologies | 12/07 | Series F | $69M | 3 |
| Oxford Immunotec | 10/07 | Series C | $40M | 6 |
| Sientra | 4/07 | Series B | $85M | 3 |
| Aerovance | 3/07 | Series C | $60M | 6 |
| Variation Biotechnologies | 1/07 | Series A | $35.7M | 3 |
| SARcode Bioscience | 12/06 | Venture Round | $29M | 2 |
| Zogenix | 8/06 | Series A | $60M | 5 |
| ESBATech | 8/06 | Series B | $41M | 7 |
